Part I. Financial Information [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) For the first six months of 2025, the company reported slightly increased revenue and a significantly reduced net loss due to the absence of prior-year impairment charges, alongside a major debt refinancing that restructured its debt and impacted cash flows [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets slightly decreased to **$5.07 billion**, total liabilities increased to **$5.11 billion**, and shareholders' equity shifted to a **$39.9 million** deficit from **$84.0 million** equity at year-end 2024, primarily due to net loss and debt refinancing Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $247,138 | $175,515 | | Cash and cash equivalents | $56,390 | $16,848 | | **Total Assets** | **$5,071,980** | **$5,150,827** | | **Total Current Liabilities** | $253,142 | $213,790 | | **Total Liabilities** | **$5,111,888** | **$5,066,805** | | **Total Shareholders' Equity (Deficit)** | **($39,908)** | **$84,022** | [Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Loss%20and%20Comprehensive%20Loss) For Q2 2025, revenues slightly increased to **$241.6 million**, and the company reported a significantly improved net loss of **$62.6 million** (or **$3.81 per share**) compared to **$576.7 million** in Q2 2024, primarily due to the absence of a **$553.7 million** goodwill impairment charge Statement of Loss Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | **Revenues** | $241,570 | $233,476 | $472,900 | $467,984 | | **Operating Income (Loss)** | $16,578 | ($523,927) | $26,320 | ($1,010,363) | | Loss on impairment | $0 | $553,701 | $0 | $1,072,751 | | **Net Loss** | **($62,640)** | **($576,727)** | **($133,959)** | **($1,116,416)** | | **Net Loss Per Share** | **($3.81)** | **($35.78)** | **($8.19)** | **($69.18)** | [Unaudited Condensed Consolidated Statements of Shareholders' Equity](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Shareholders%27%20Equity) Shareholders' equity transitioned from **$84.0 million** at year-end 2024 to a **$39.9 million** deficit as of June 30, 2025, primarily due to the **$134.0 million** net loss for the six-month period - The company's retained deficit increased from **$(2,145.1) million** at the end of 2024 to **$(2,279.1) million** at June 30, 2025, due to the net loss incurred during the first half of the year[21](index=21&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2025, net cash from operating activities decreased to **$31.2 million**, investing activities used **$63.5 million**, and financing activities provided **$69.9 million**, a significant reversal from the prior year, largely due to **$130 million** in new borrowings Cash Flow Summary (in thousands) | Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | **Net Cash from Operating Activities** | $31,181 | $68,187 | | **Net Cash used in Investing Activities** | ($63,489) | ($55,989) | | **Net Cash from (used in) Financing Activities** | $69,924 | ($34,523) | | **Net Change in Cash** | $37,616 | ($22,325) | [Notes to Unaudited Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail significant corporate actions, including the company's name change to Claritev Corporation, a 1-for-40 reverse stock split in 2024, a major debt refinancing in January 2025, and disclosures on revenue, goodwill (with no impairments in 2025), derivatives, and ongoing legal matters - On February 17, 2025, the company changed its name from "MultiPlan Corporation" to "**Claritev Corporation**" and its ticker symbol to "**CTEV**"[26](index=26&type=chunk) - A **one-for-forty (1-for-40) reverse stock split** of its Class A common stock became effective on **September 20, 2024**. All share and per-share data have been retroactively adjusted[29](index=29&type=chunk)[30](index=30&type=chunk) - In **January 2025**, the company completed a major **Refinancing Transaction**, exchanging existing notes and term loans for new first lien term loans and notes with extended maturities, and establishing a new **$350 million revolving credit facility**[56](index=56&type=chunk) - The company recorded **no goodwill impairment in the first six months of 2025**, compared to a significant impairment loss of **$1,072.8 million** in the same period of 2024[42](index=42&type=chunk)[75](index=75&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management reported a **1.1%** revenue increase for the first six months of 2025, driven by Network-Based and Payment and Revenue Integrity Services, with a significantly narrowed net loss due to the absence of 2024 impairment charges, while a January 2025 debt refinancing extended maturities and Adjusted EBITDA slightly increased to **$296.1 million** - The company initiated its first international expansion into the **Middle East and North Africa (MENA) region** through a strategic partnership with Claims Care Revenue Cycle Management LLC[98](index=98&type=chunk) Revenue by Service Line (in thousands) | Service Line | Six Months 2025 | Six Months 2024 | Change % | | :--- | :--- | :--- | :--- | | Network-Based Services | $101,015 | $91,878 | +9.9% | | Analytics-Based Services | $310,396 | $319,988 | -3.0% | | Payment and Revenue Integrity | $61,489 | $56,118 | +9.6% | | **Total Revenues** | **$472,900** | **$467,984** | **+1.1%** | Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Metric | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | | Net loss | ($133,959) | ($1,116,416) | | Adjustments | $430,056 | $1,409,876 | | **Adjusted EBITDA** | **$296,097** | **$293,460** | - General and administrative expenses increased by **49.2%** for the six months ended June 30, 2025, primarily due to **$15.7 million** in transformation costs and **$5.5 million** in losses on asset disposals[143](index=143&type=chunk) - As of June 30, 2025, the company had **$67.3 million** in cash and cash equivalents (including restricted cash) and **$263.6 million** of availability under its revolving credit facility[154](index=154&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that as of June 30, 2025, there have been no material changes in the market risks it faces compared to those described in its 2024 Annual Report - There were no material changes in the market risks described in the company's 2024 Annual Report as of June 30, 2025[188](index=188&type=chunk) [Controls and Procedures](index=45&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, noting the implementation of a new enterprise resource planning (ERP) system during the quarter, which led to new and modified internal controls - The principal executive and financial officers concluded that disclosure controls and procedures were effective as of June 30, 2025[190](index=190&type=chunk) - During the second quarter of 2025, the company completed the implementation of a **new enterprise resource planning (ERP) system**, resulting in changes to its internal control over financial reporting[191](index=191&type=chunk) Part II - Other Information [Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal proceedings arising from the ordinary course of business, which management does not expect to have a material adverse effect on its financial condition or operations - The company is a defendant in various lawsuits and regulatory investigations arising from the ordinary course of business but does not expect them to have a material adverse effect[194](index=194&type=chunk) [Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) While no material changes occurred to overall risk factors from the 2024 Annual Report, new risks emerged from international expansion, including challenges in managing foreign operations, complying with international laws, and increased susceptibility to global economic and political events - The company faces **new risks associated with its international business expansion**, including managing foreign operations, complying with international laws, and dealing with political or economic instability in foreign countries[201](index=201&type=chunk)[206](index=206&type=chunk) - As the company expands its international footprint, it becomes more susceptible to global events beyond its control, such as changes in trade policy, military conflict, and public health crises[203](index=203&type=chunk) [Other Information](index=48&type=section&id=Item%205.%20Other%20Information) During the second quarter of 2025, no officers or directors of the company adopted or terminated any Rule 10b5-1 trading plans for the purchase or sale of company securities - **No officers or directors adopted or terminated any Rule 10b5-1(c) trading arrangements** during the three months ended June 30, 2025[208](index=208&type=chunk) [Exhibits](index=48&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer as required by the Sarbanes-Oxley Act of 2002, and financial statements in Inline XBRL format - The report includes certifications from the CEO and CFO pursuant to **Sections 302 and 906 of the Sarbanes-Oxley Act of 2002**[208](index=208&type=chunk)

EXHIBIT 99.1 E Claritev Corporation Reports Second Quarter 2025 Results McLean, VA — August 6, 2025 — Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the second quarter ended June 30, 2025. Business and Financial Highlights – Q2 2025 Revenues of $241.6 million, Net Loss of 62.6 million, and Adjusted EBITDA of $154.0 million (Adjusted EBITDA ...

Financial Position - As of March 31, 2025, the Company had total long-term debt of $4,555.15 million, with a fair value of $3,408.53 million[66]. - The fair value of long-term debt is estimated using Level 2 inputs, as these are not registered securities nor listed on any exchange[66]. - The Company had cash and cash equivalents of $10.0 million as of March 31, 2025, which included money market funds valued based on Level 1 measurements[64]. - The Company has irrevocable letters of credit totaling $5.2 million outstanding as of March 31, 2025, related to real estate lease agreements and a captive insurance subsidiary[71]. Revenue and Income - Revenues for the three months ended March 31, 2025, were $231.33 million, a decrease of 1% from $234.51 million in the same period of 2024[80]. - Operating income for Q1 2025 was $9.74 million, compared to an operating loss of $486.44 million in Q1 2024[80]. - Net loss for the three months ended March 31, 2025, was $71.32 million, significantly improved from a net loss of $539.69 million in Q1 2024[81]. - Basic and diluted net loss per share for Q1 2025 was $(4.38), compared to $(33.40) for Q1 2024[81]. Expenses - Total expenses for Q1 2025 were $221.59 million, down from $720.94 million in Q1 2024, reflecting a substantial reduction in costs[80]. - General and Administrative expenses increased to $50.64 million in Q1 2025 from $34.86 million in Q1 2024, primarily due to higher personnel costs and other G&A expenses[80]. - Interest expense for Q1 2025 was $91.64 million, up from $82.20 million in Q1 2024[80]. - Related party expenses amounted to $19 thousand in Q1 2025, down from $36 thousand in Q1 2024[82]. Impairment and Litigation - There were no impairment charges for the three months ended March 31, 2025, while impairment charges of $519.1 million were recorded for the same period in 2024[69]. - The company reported no loss on impairment of goodwill and intangible assets in Q1 2025, contrasting with a loss of $519.05 million in Q1 2024[80]. - The Company believes that ongoing litigation will not have a material adverse effect on its financial condition or results of operations[72]. - The Company received $9.8 million in recoveries from insurers related to a settled litigation case in the three months ended September 30, 2024[73]. Operational Overview - The Company operates as a single segment focused on providing data analytics and technology-enabled cost management solutions to the U.S. healthcare industry[76]. - The Company has identified significant expenses including personnel costs, stock-based compensation, and access and bill review fees, which are regularly reviewed by the Chief Operating Decision Maker[77]. - The Company recorded no value for the 476,717 Private Placement Warrants and 310,102 Unvested Founder Shares as of March 31, 2025[61]. Share Information - The weighted average number of shares outstanding for basic and diluted calculations was 16,273,439 for Q1 2025, compared to 16,158,356 for Q1 2024[81].

EXHIBIT 99.1 E Claritev Corporation Reports First Quarter 2025 Results McLean, VA — May 8, 2025 — Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2025. "There is tremendous excitement at Claritev as we kick off 2025 - our 'Year of The Turn.' We've already announced major milestones, and our teams are amplif ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 o For the transition period from to Commission file number: 001-39228 CLARITEV CORPORATION (Exact Name of Registrant as Specified in Its Charter) Delaware 84-3536151 (State or other ...

Claritev Corporation (NYSE:MPLN) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Shawna Gasik - Assistant Vice President, Investor Relations Travis Dalton - Chief Executive Officer Doug Garis - Chief Financial Officer Conference Call Participants Joshua Raskin - Nephron Research Daniel Grosslight - Citigroup Jessica Tassan - Piper Sandler Operator Hello all, and welcome to today's Claritev Corporation Fourth Quarter 2024 Earnings Call. My name is Drew, and I will be the op ...

MultiPlan Corporation (MPLN) came out with a quarterly loss of $5.14 per share versus the Zacks Consensus Estimate of a loss of $2.33. This compares to loss of $2.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -120.60%. A quarter ago, it was expected that this company would post a loss of $2.37 per share when it actually produced a loss of $1.85, delivering a surprise of 21.94%.Over the last four quarters, the company has ...

Claritev Q4 & FY 2024 Results and Business Update February 25, 2025 1 Disclaimer Forward-Looking Statements This presentation includes statements that express our management's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements". These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estim ...

EXHIBIT 99.1 Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025 NEW YORK, NY — February 25, 2025 — Claritev Corporation ("Claritev" or the "Company") (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalton said, "We are cel ...

MultiPlan Corporation (MPLN) - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [1] - The stock price rallied 15.5% in the last trading session to close at $14.70, driven by notable trading volume [3] - The stock has gained 76.6% over the past four weeks [3] - The company is expected to post a quarterly loss of $2.33 per share, representing a year-over-year change of +2.9% [5] - Revenues are expected to be $236.74 million, down 3% from the year-ago quarter [5] - The recent price increase is attributed to investor optimism surrounding the company's decision to consolidate its cloud infrastructure on Oracle Cloud Infrastructure (OCI) as part of its digital transformation strategy [4] Medpace (MEDP) - The consensus EPS estimate for the upcoming report has increased by +0.9% over the past month to $2.97, representing a +20.7% change from the same period last year [2] - The stock closed the last trading session 0.3% higher at $352.01 [1] - Over the past month, the stock has returned 1.4% [1] Industry Context - MultiPlan belongs to the Zacks Medical Services industry [1] - Medpace is another stock in the same industry [1]